What is OCT — and how do we use it in the Valeda Clinic to track macular health and treatment response?

If you’ve been told you have dry age-related macular degeneration (dry AMD)—or it runs in your family—you’ll know how frustrating the usual advice can feel: “monitor it,” “take supplements,” “come back in 6–12 months.” Monitoring matters, but how we monitor matters even more.

At Peter Ivins Eye Care (Bearsden, Scotland), our Valeda Clinic was built around a simple principle: when you have a progressive macular condition, you deserve the earliest possible detection of change, the best-quality imaging, and expert interpretation—every visit. The cornerstone of that approach is Optical Coherence Tomography (OCT)—the single most important test for “seeing” dry AMD in cross-section and tracking it over time.

This article explains:

• what OCT is (in plain English)
• what OCT can reveal in dry AMD that routine eye tests can’t
• why the grade of OCT matters (and why we use ZEISS technology)
• how we combine OCT with advanced software and AI to detect tiny changes
• how OCT is used in the Valeda pathway to assess suitability and track outcomes

Quick takeaway: OCT doesn’t just “take a picture.” It creates a microscopic, cross-sectional map of your retina—allowing us to monitor AMD progression and response to treatment with far greater precision than standard examinations alone.

What is OCT (Optical Coherence Tomography)?

Think of OCT as the eye’s version of an MRI or ultrasound, but using light rather than sound. It produces high-resolution cross-sectional scans of the retina—layer by layer—so we can detect changes beneath the surface long before symptoms become obvious.

Modern OCT systems capture dense 3D data (“cubes”) of the macula and can repeat those scans with excellent alignment visit-to-visit, allowing clinicians to track subtle change over time. High-performance systems can also image a larger retinal area quickly, helping reduce motion artefact and improving the reliability of follow-up comparisons.

Why OCT is essential in dry AMD (and why a “standard eye test” isn’t enough)

Dry AMD is primarily a disease of the macula—the central part of the retina responsible for detailed vision. In its earlier stages, the structures that change are often microscopic and beneath the visible surface.

OCT helps us visualise and quantify key AMD-related findings such as:

• Drusen (deposits beneath the retina)
• changes to the retinal pigment epithelium (RPE)
• early atrophy signals and tissue loss
• subtle fluid patterns that can suggest conversion to more active disease pathways
• structural markers that can be used to monitor progression

Because OCT is fast and non-invasive, it’s ideal for regular monitoring—especially where the goal is to detect small changes early and respond with timely clinical decisions. High-speed acquisition also reduces repeat scans and chair time while improving image consistency.

Why the grade of OCT matters: “Not all OCTs are equal”

If you’ve had an OCT elsewhere, you may reasonably ask: “Isn’t an OCT just an OCT?”
In reality, OCT devices vary significantly in:

• scan speed (how quickly data is captured)
• field of view (how much retina is scanned in one go)
• resolution and noise control (how clear the layers are)
• tracking technology (how well scans align between visits)
• analysis tools (how accurately change is measured over time)

Our choice: ZEISS CIRRUS 6000 Performance OCT

In the Valeda Clinic, we use ZEISS CIRRUS 6000 Performance OCT as part of our macular disease management pathway.

ZEISS CIRRUS 6000 is a next-generation OCT platform capable of 100,000 scans per second, enabling high-speed capture and larger single-scan fields (up to 12 mm in one scan), supporting detailed structural OCT and OCT angiography imaging.

Why this matters clinically:

• Speed reduces motion artefact (blinks, micro-movements) and improves scan reliability.
• Larger scan areas can capture more macular context in one acquisition, supporting informed decisions.
• High-definition options (including advanced averaging approaches) can improve clarity of subtle retinal layer change.
• FastTrac™ eye tracking supports image stability and reduces the need for repeat captures.

In dry AMD, where we may be trying to detect tiny changes in drusen architecture or early atrophy signals, these performance differences are not trivial—they are the difference between “we think it’s stable” and “we can prove it’s stable (or not).”

OCT’s role in the Valeda Clinic: suitability, baseline, and tracking response

Valeda photobiomodulation (PBM) is supported by clinical research programs evaluating visual outcomes and anatomical markers in non-exudative (dry) AMD. Registry data collection has also emphasised the role of OCT and fundus autofluorescence (FAF) in ongoing monitoring after PBM treatment rounds.

At Peter Ivins Eye Care, our OCT pathway typically supports three crucial stages:

1) Establishing a high-quality baseline

Before any treatment plan, we need a precise “starting point.” OCT provides:

• macular structure maps
• drusen and RPE morphology documentation
• repeatable scan protocols for robust follow-up

This baseline becomes your “reference scan”—the benchmark we use to judge whether your macula is stable or changing.

2) Confirming suitability and safety

OCT helps identify features that may alter management decisions and also helps guide whether other investigations (e.g., OCT-A or referral) are needed. High-performance OCT can support efficient acquisition and detailed review in a clinic workflow.

3) Tracking response and progression over time

Dry AMD is often slow-moving—so meaningful monitoring needs:

• consistent scan positioning
• strong visit-to-visit comparability
• longitudinal analysis tools

This is where our software ecosystem becomes as important as the camera.

“Seeing change” over time: ZEISS Retina Workplace (and why it’s a big deal)

Capturing great images is only half the battle. The other half is comparing the right scans, in the right alignment, across multiple visits—without losing clinically meaningful details.

ZEISS Retina Workplace: integrated multimodality review

ZEISS describes Retina Workplace as multimodality software that can synchronise and register different imaging types—so clinicians can review correlated data (e.g., OCT cubes with fundus images) and compare multiple exams for change detection and longitudinal management.

Key capabilities highlighted by ZEISS include:

• reviewing synchronised data such as OCT cubes registered with raster scans and fundus images
• comparing up to three exams in one view to identify change over time
• registering ultra-widefield fundus images with OCT angiography images in one interface

Why this matters for dry AMD and Valeda monitoring:
Dry AMD progression can be subtle: incremental structural changes, slow drusen evolution, early atrophy signals. A platform that makes longitudinal comparison faster and more consistent helps clinicians detect clinically relevant change earlier and communicate it more clearly to patients.

Adding AI to the workflow: Altris AI (how it supports tracking)

Peter Ivins Eye Care also embraces AI-assisted analysis as part of a modern retinal monitoring strategy.

Altris AI describes its OCT workflow tools as supporting detection of 70+ retinal pathologies/biomarkers and includes features designed to help clinicians track conditions over time—particularly where quantitative monitoring (such as for geographic atrophy and fluid biomarkers) is useful.

In publications about platform enhancements, Altris AI has been reported to include quantification and progression tracking features designed to visualise changes over time and support timely management decisions in retinal disease monitoring contexts.

Our clinic philosophy on AI:
AI doesn’t replace expert optometric judgement—it supports it. The goal is:

• more consistent detection of subtle structural markers
• better visual explanations for patients
• clearer longitudinal change tracking

When you combine high-quality imaging, registered longitudinal software, and AI-supported progression tools, you get a clinic designed around early detection and confident monitoring—exactly what dry AMD patients need.

Why our Valeda Clinic approach is different (expertise + technology + leadership)

Peter Ivins Eye Care has a long-standing reputation for macular care leadership in Scotland—particularly in the application of advanced imaging to real-world clinical decision-making.

In the Valeda era, that experience matters because Valeda outcomes and safety monitoring rely on robust clinical assessment and imaging follow-up. Registry study protocols and Valeda clinical research discussions frequently reference the collection of outcomes such as visual acuity and retinal imaging markers (including OCT and FAF) across multiple treatment rounds.

Our aim is simple: give patients the best chance of preserving functional vision by detecting change early and providing evidence-informed options—supported by high-grade diagnostics and an experienced clinical team.

What you can expect at OCT appointments in the Valeda Clinic

Most OCT appointments are straightforward:

• quick scan acquisition
• immediate review and explanation in plain language

Where appropriate, we’ll show you:

• your macular layers
• any drusen/RPE changes
• how your scans compare with previous visits (side-by-side)
• what this means for monitoring and treatment planning

And importantly: we’ll translate the science into practical next steps.

Book a Valeda suitability assessment or ask an expert

If you have dry AMD, drusen, early macular changes—or a family history—and you’re searching for:

• “Valeda clinic Scotland”
• “photobiomodulation dry AMD”
• “OCT monitoring for macular degeneration”
• “private macular clinic near Glasgow”

…we can help.

Book a Valeda suitability assessment at Peter Ivins Eye Care
Or send a question for Craig McArthur—and we’ll point you in the right direction with honest, evidence-informed guidance.

Book Now

…we can help you understand your baseline, your risk, and your options.

📞 Call us: 0141 943 3300
📍 Visit our clinic in Bearsden, Glasgow
📅 Book a Valeda Assessment online

Learn more at www.valedascotland.co.uk

FAQ’s

FAQ 1: What does an OCT scan show in dry AMD?
An OCT scan shows cross-sectional layers of the retina, helping clinicians identify drusen, RPE changes and early structural signs of progression that may not be visible on routine examination.

FAQ 2: How often should OCT be done for dry AMD?
This depends on AMD stage, risk factors, and clinical findings; many monitoring pathways rely on repeatable OCT imaging to compare scans over time and detect change early.

FAQ 3: Why does the OCT machine matter?
Higher-performance OCT can capture larger scans quickly and with high definition, improving scan consistency and reducing motion artefact—important for reliable comparisons over time.

FAQ 4: What is ZEISS Retina Workplace used for?
It is multimodality software designed to synchronise and register imaging (including OCT and other modalities) and compare multiple visits to detect changes over time.  

FAQ 5: Can AI help interpret OCT scans?
AI platforms can support detection and tracking of retinal biomarkers over time, helping clinicians visualise progression and quantify certain features in monitoring workflows.